GlobalRPh Renal Dosing Masterv6.6
Source review / handoff

Cefazolin

One or two intact local summaries. No averaged regimen, patient-specific dose or automatic source preference.

Return to full drug recordRead selected sourcesHow to use this review

Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.

Share or print this source review

1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.

Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.

Clinical context remains essential

Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.

The source summary says "Maximum interval: q8h" whereas its package-insert paragraph specifies at least 8-hour intervals. This wording conflict is preserved for review.

Check source scope before reading a dose

UCSF - cefazolin

Product / population
Adults; source-specific institutional guidance. Match route, indication and renal replacement modality.
Renal method
CrCl in mL/min where specified; no equation inferred.
Source revision
Revision date not stated in the reviewed page.
Retrieved
2026-09-05
Local review status
Locally included source-specific summary. Regimen differences are not automatically resolved.
Professional

UCSF - cefazolin

Open original reference

UCSF Infectious Diseases Management Program · Adults; source-specific institutional guidance. Match route, indication and renal replacement modality.

Renal method: CrCl in mL/min where specified; no equation inferred.
Source date: Revision date not stated in the reviewed page.
Retrieved: 2026-09-05

Locally included source-specific summary. Regimen differences are not automatically resolved.

Dosing / renal protocol and limits

Limits that apply to these rows

Exactly 30 is not assigned. Deep MSSA infection with clinical instability may need individualized higher dosing. Keep dialysis stability and the 72-hour gap attached to the alternative.

Uncomplicated Gram-positive infection - IV
CrCl, mL/minSource-specific dose / instruction
>301 g every 8 hours
10-291 g every 12 hours
<101 g every 24 hours
Complicated Gram-positive or Gram-negative infection - IV
CrCl, mL/minSource-specific dose / instruction
>302 g every 8 hours
10-292 g every 12 hours
<101 g every 24 hours
Dialysis guidance - separate source-specific schedules
UCSF cefazolin dialysis
Dialysis setting / indicationSource-specific schedule
IHD2 g initially and after HD
Stable thrice-weekly IHD alternative2 g / 2 g / 3 g after HD; 3 g precedes the 72-hour gap
CVVHD2 g IV every 12 hours
Read the retained text before reformatting

For CrCl >30 / 10-29 / <10 mL/min:

  • Uncomplicated Gram-positive infection: 1 g IV every 8 / 12 / 24 hours.
  • Complicated Gram-positive or Gram-negative infection: 2 g IV every 8 hours / 2 g every 12 hours / 1 g daily.

Deep MSSA infection with clinical instability may need individualized higher dosing.

IHD: 2 g initially and after HD. Stable thrice-weekly dialysis permits the alternative 2 g / 2 g / 3 g post-HD sequence, with 3 g preceding the 72-hour interdialytic gap. CVVHD: 2 g IV every 12 hours.

Exactly 30 mL/min is not assigned by the published >30 and 10-29 columns.

RDM30-011-cefazolin-1 · Source locator: UCSF - cefazolin; renal/dosing sections and stated qualifiers

Source identity and provenance
Source
https://idmp.ucsf.edu/content/cefazolin
Retrieved
2026-09-05
Renal-function method
CrCl in mL/min where specified; no equation inferred.
Source date/version
Revision date not stated in the reviewed page.
Hash meaning
Locally authored summary text; not original SPL, HTML or PDF bytes
Local summary SHA-256
e40b67b76c05828e2f913d65de9d20679143486edaf7cb92fc308cf32eab98c5

Document the clinical decision separately

This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.

GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.

Pinned reference: https://globalrph.com/blogCalcs/renal-dosing-master/compare.php?id=cefazolin&s1=RDM30-011-cefazolin&h1=c7c33199634b7e856e6c25b68c56505b3438797c51e34b3e49cdc764fb4e9769